Dave joined EyeBio in April, 2024. He leads our financial strategy and operations. Dave joins us from Iveric Bio where he was CFO until its sale for $5.9 billion. As CFO, Dave developed and led the financing strategy that raised $1.2 billion in capital and enabled Iveric’s evolution to a commercial organization. During his 30 years in life sciences, Dave has held a variety of financial leadership positions at The Medicines Company, Genentech, Novartis and Bristol-Myers Squibb.
Dave is a certified public accountant and received a BA from Ursinus College, magna cum laude and an MBA from Rutgers University.
